The abstract is read at the publisher; the summary is JClub's.
Hepatitis E virus has become a significant cause of chronic hepatitis and extrahepatic disease in immunocompromised patient groups over the last 15 years, including transplant recipients and advanced HIV.
- Why it matters: The field has shifted from viewing HEV as acute and self-limited to recognizing higher-risk outcomes in immunosuppressed people, including those receiving newer targeted therapies and CAR T-cell treatments.
- What they did: This review integrates evidence on HEV epidemiology, clinical manifestations, pathogenesis, diagnosis, and management across immunocompromised host categories, including zoonotic reservoirs, transmission routes, and disease models.
- The result: The synthesis highlights clinical and research implications for HEV in vulnerable patients and supports updated approaches to diagnosis and management in these immunocompromised settings.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.